-
C.
Herzog
(2016)
Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR.
Travel medicine and infectious disease, 14 4
-
D.
Haney,
Michael
Lock,
J.
Simon,
J.
Harris,
M.
Gurwith
(2017)
Antibody-Based Correlates of Protection against Cholera: Analysis of a Challenge Study of a Cholera-Naive Population
Clinical and Vaccine Immunology : CVI, 24
-
W.
Ratanasuwan,
Y.
Kim,
B.
Sah,
S.
Suwanagool,
D.
Kim,
A.
Anekthananon,
A.
Lopez,
W.
Techasathit,
S.
Grahek,
J.
Clemens,
T.
Wierzba
(2015)
Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand.
Vaccine, 33 38
-
F.
Luquero,
L.
Grout,
I.
Ciglenecki,
Keita
Sakoba,
B.
Traore,
Melat
Heile,
A.
Diallo,
Christian
Itama,
A.
Page,
M.
Quilici,
Martin
Mengel,
J.
Eiros,
M.
Serafini,
D.
Legros,
R.
Grais
(2014)
Use of Vibrio cholerae vaccine in an outbreak in Guinea.
The New England journal of medicine, 370 22
-
M.
Rennels,
M.
Levine,
V.
Daya,
P.
Angle,
C.
Young
(1980)
Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories.
The Journal of infectious diseases, 142 3
-
J.
Simon,
M.
Maciel,
M.
Maciel,
E.
Weld,
R.
Wahid,
M.
Pasetti,
W.
Picking,
K.
Kotloff,
M.
Levine,
M.
Sztein
(2011)
Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.
Clinical immunology, 139 2
-
S.
Buuren,
J.
Brand,
C.
Groothuis-Oudshoorn,
D.
Rubin
(2006)
Fully conditional specification in multivariate imputation
Journal of Statistical Computation and Simulation, 76
-
(2010)
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine
, 8
-
Eduardo
Gotuzzo,
Betzabé
Butrón,
C.
Seas,
Mary
Penny,
Rosa
Ruiz,
G.
Losonsky,
Claudio
Lanata,
Steven
Wasserman,
Eduardo
Salazar,
J.
Kaper,
S.
Cryz,
M.
Levine
(1993)
Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels
Infection and Immunity, 61
-
W.
Mosley,
A.
Benenson,
R.
Barui
(1968)
A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera.
Bulletin of the World Health Organization, 38 3
-
Rosanna
Lagos,
Alfredo
Avendano,
Valeria
Prado,
I.
Horwitz,
Steven
Wasserman,
G.
Losonsky,
S.
Cryz,
J.
Kaper,
M.
Levine
(1995)
Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O
Infection and Immunity, 63
-
S.
Kanungo,
A.
Paisley,
A.
Lopez,
M.
Bhattacharya,
B.
Manna,
Deok-ryun
Kim,
S.
Han,
S.
Attridge,
R.
Carbis,
R.
Rao,
J.
Holmgren,
J.
Clemens,
D.
Sur
(2009)
Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
Vaccine, 27 49
-
Y.
Baik,
S.
Choi,
R.
Olveda,
R.
Espos,
Antonio
Ligsay,
M.
Montellano,
Jong
Yeam,
J.
Yang,
J.
Park,
Deok-ryun
Kim,
Sachin
Desai,
A.
Singh,
I.
Kim,
C.
Kim,
Sue-nie
Park
(2015)
A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Vaccine, 33 46
-
T.
Wierzba,
S.
Kar,
Vijayalaxmi
Mogasale,
A.
Kerketta,
Y.
You,
Prameela
Baral,
H.
Khuntia,
Mohammad
Ali,
Y.
Kim,
S.
Rath,
A.
Bhattachan,
B.
Sah
(2015)
Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India.
Vaccine, 33 21
-
Prado,
Paulina
Abrego,
Myron
Levine,
P.
Losonsky,
Steven
Wasserman,
O.
Martín
(1996)
Tolerancia, inmunogenicidad, excreción y transmisión de la vacuna anti-cólera oral viva-atenuada, CVD 103-HgR. Estudio pareado doble ciego en niños chilenos de 24 a 59 meses
Boletín médico del Hospital Infantil de México, 53
-
J.
Harris,
R.
Larocque,
F.
Chowdhury,
A.
Khan,
T.
Logvinenko,
A.
Faruque,
E.
Ryan,
F.
Qadri,
S.
Calderwood
(2008)
Susceptibility to Vibrio cholerae Infection in a Cohort of Household Contacts of Patients with Cholera in Bangladesh
PLoS Neglected Tropical Diseases, 2
-
Suharyono,
C.
Simanjuntak,
H.
Totosudirjo,
N.
Witham,
N.
Punjabi,
D.
Burr,
K.
Sorenson,
D.
Heppner,
G.
Losonsky,
J.
Clemens,
Y.
Lim,
S.
Wasserman,
J.
Kaper,
Myron
Levine,
A.
Rifai,
S.
Cryz
(1992)
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children
The Lancet, 340
-
R.
Lagos,
O.
Martin,
S.
Wasserman,
V.
Prado,
G.
Losonsky,
Cecilia
Bustamante,
M.
Levine
(1999)
Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
The Pediatric infectious disease journal, 18 7
-
M.
Levine,
Wilbur
Chen,
J.
Kaper,
Michael
Lock,
L.
Danzig,
M.
Gurwith
(2017)
PaxVax CVD 103-HgR single-dose live oral cholera vaccine
Expert Review of Vaccines, 16
-
J.
Ketley,
J.
Michalski,
J.
Galen,
M.
Levine,
J.
Kaper
(1993)
Construction of genetically marked Vibrio cholerae O1 vaccine strains.
FEMS microbiology letters, 111 1
-
W.
Mosley,
S.
Ahmad,
A.
Benenson,
A.
Ahmed
(1968)
The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients.
Bulletin of the World Health Organization, 38 5
-
M.
Clements,
M.
Levine,
C.
Young,
R.
Black,
Y.
Lim,
R.
Robins-Browne,
J.
Craig
(1982)
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.
The Journal of infectious diseases, 145 4
-
P.
Calain,
J.
Chaine,
Eliaser
Johnson,
M.
Hawley,
M.
O'leary,
H.
Oshitani,
C.
Chaignat
(2004)
Can oral cholera vaccination play a role in controlling a cholera outbreak?
Vaccine, 22 19
-
R.
Perry,
C.
Plowe,
B.
Koumaré,
F.
Bougoudogo,
K.
Kotloff,
G.
Losonsky,
Steven
Wasserman,
M.
Levine
(1998)
A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
Bulletin of the World Health Organization, 76 1
-
C.
Tacket,
Mitchell
Cohen,
S.
Wasserman,
G.
Losonsky,
Sofie
Livio,
K.
Kotloff,
R.
Edelman,
J.
Kaper,
S.
Cryz,
R.
Giannella,
G.
Schiff,
M.
Levine
(1999)
Randomized, Double-Blind, Placebo-Controlled, Multicentered Trial of the Efficacy of a Single Dose of Live Oral Cholera Vaccine CVD 103-HgR in Preventing Cholera following Challenge with Vibrio cholerae O1 El Tor Inaba Three Months after Vaccination
Infection and Immunity, 67
-
F.
Qadri,
T.
Wierzba,
Mohammad
Ali,
F.
Chowdhury,
A.
Khan,
A.
Saha,
I.
Khan,
M.
Asaduzzaman,
A.
Akter,
Arifuzzaman
Khan,
Y.
Begum,
T.
Bhuiyan,
F.
Khanam,
M.
Chowdhury,
Taufiqul
Islam,
A.
Chowdhury,
Anisur
Rahman,
S.
Siddique,
Y.
You,
Deok
Kim,
A.
Siddik,
N.
Saha,
Alamgir
Kabir,
A.
Cravioto,
Sachin
Desai,
A.
Singh,
J.
Clemens
(2016)
Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.
The New England journal of medicine, 374 18
-
F.
Qadri,
Mohammad
Ali,
F.
Chowdhury,
A.
Khan,
A.
Saha,
I.
Khan,
Y.
Begum,
T.
Bhuiyan,
M.
Chowdhury,
M.
Uddin,
Jahangir
Khan,
A.
Chowdhury,
Anisur
Rahman,
S.
Siddique,
M.
Asaduzzaman,
A.
Akter,
Arifuzzaman
Khan,
Y.
You,
A.
Siddik,
N.
Saha,
Alamgir
Kabir,
B.
Riaz,
S.
Biswas,
F.
Begum,
L.
Unicomb,
S.
Luby,
A.
Cravioto,
J.
Clemens
(2015)
Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial
The Lancet, 386
-
Pisit
Su-Arehawaratana,
P.
Singharaj,
David
Taylor,
Charles
Hoge,
A.
Trofa,
K.
Kuvanont,
S.
Migasena,
P.
Pitisuttitham,
Y.
Lim,
G.
Losonsky,
J.
Kaper,
S.
Wasserman,
S.
Cryz,
P.
Echeverria,
M.
Levine
(1992)
Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand.
The Journal of infectious diseases, 165 6
-
C.
Simanjuntak,
Peter
O’Hanley,
N.
Punjabi,
Fernando
Noriega,
Gary
Pazzaglia,
Patricia
Dykstra,
B.
Kay,
Suharyono,
Aswitha
Budiarso,
Atti
Rifai,
Steven
Wasserman,
G.
Losonsky,
J.
Kaper,
S.
Cryz,
M.
Levine
(1993)
Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children.
The Journal of infectious diseases, 168 5
-
R.
Glass,
A.
Svennerholm,
M.
Khan,
S.
Huda,
M.
Huq,
J.
Holmgren
(1985)
Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.
The Journal of infectious diseases, 151 2
-
Wilbur
Chen,
Mitchell
Cohen,
B.
Kirkpatrick,
R.
Brady,
David
Galloway,
M.
Gurwith,
R.
Hall,
Robert
Kessler,
Michael
Lock,
D.
Haney,
Caroline
Lyon,
M.
Pasetti,
J.
Simon,
Flora
Szabo,
S.
Tennant,
M.
Levine
(2016)
Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 62 11
-
MyronM.
Levine,
D.
Herrington,
G.
Losonsky,
B.
Tall,
J.
Kaper,
J.
Ketley,
C.
Tacket,
S.
Cryz
(1988)
SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgR
The Lancet, 332
-
E.
Barzilay,
N.
Schaad,
R.
Magloire,
K.
Mung,
J.
Boncy,
G.
Dahourou,
E.
Mintz,
Maria
Steenland,
J.
Vertefeuille,
J.
Tappero
(2013)
Cholera surveillance during the Haiti epidemic--the first 2 years.
The New England journal of medicine, 368 7
-
A.
Saha,
M.
Chowdhury,
F.
Khanam,
Md
Bhuiyan,
F.
Chowdhury,
A.
Khan,
I.
Khan,
J.
Clemens,
Mohammad
Ali,
A.
Cravioto,
F.
Qadri
(2011)
Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Vaccine, 29 46
-
R.
Wahid,
J.
Simon,
W.
Picking,
K.
Kotloff,
M.
Levine,
M.
Sztein
(2013)
Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.
Clinical immunology, 148 1
-
Robert
Kauffman,
T.
Bhuiyan,
R.
Nakajima,
Leslie
Mayo-Smith,
R.
Rashu,
M.
Hoq,
F.
Chowdhury,
A.
Khan,
Atiqur
Rahman,
S.
Bhaumik,
Levelle
Harris,
Justin
O’neal,
Jessica
Trost,
N.
Alam,
A.
Jasinskas,
Emmanuel
Dotsey,
Meagan
Kelly,
R.
Charles,
Peng
Xu,
P.
Kováč,
S.
Calderwood,
E.
Ryan,
P.
Felgner,
F.
Qadri,
J.
Wrammert,
J.
Harris
(2016)
Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells
mBio, 7
-
D.
Swerdlow,
K.
Greene,
R.
Tauxe,
J.
Wells,
N.
Bean,
A.
Ries,
P.
Blake,
E.
Mintz,
M.
Pollack,
M.
Rodriguez,
E.
Tejada,
L.
Seminario,
C.
Ocampo,
B.
Vertiz,
L.
Espejo,
W.
Saldaña
(1992)
Waterborne transmission of epidemic cholera in Trujillo, Peru: lessons for a continent at risk
The Lancet, 340
-
W.
Mosley,
W.
Mccormack,
A.
Ahmed,
A.
Chowdhury,
R.
Barui
(1969)
Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae.
Bulletin of the World Health Organization, 40 2
-
K.
Kotloff,
J.
Nataro,
W.
Blackwelder,
Dilruba
Nasrin,
T.
Farag,
S.
Panchalingam,
Yukun
Wu,
S.
Sow,
D.
Sur,
R.
Breiman,
A.
Faruque,
A.
Zaidi,
D.
Saha,
P.
Alonso,
B.
Tamboura,
Doh
Sanogo,
U.
Onwuchekwa,
B.
Manna,
T.
Ramamurthy,
S.
Kanungo,
J.
Ochieng,
R.
Omore,
J.
Oundo,
A.
Hossain,
S.
Das,
Shahnawaz
Ahmed,
S.
Qureshi,
Farheen
Quadri,
R.
Adegbola,
R.
Adegbola,
M.
Antonio,
M.
Hossain,
A.
Akinsola,
I.
Mandomando,
T.
Nhampossa,
S.
Acácio,
Kousick
Biswas,
C.
O’Reilly,
E.
Mintz,
Lynette
Berkeley,
Lynette
Berkeley,
K.
Muhsen,
H.
Sommerfelt,
H.
Sommerfelt,
R.
Robins-Browne,
M.
Levine
(2013)
Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study
The Lancet, 382
-
M.
Levine
(2010)
developing countries: lessons from a live cholera vaccine
-
E.
Richie,
N.
Punjabi,
Yuwono
Sidharta,
Kenny
Peetosutan,
Melanie
Sukandar,
Steven
Wasserman,
Murad
Lesmana,
F.
Wangsasaputra,
Sri
Pandam,
M.
Levine,
Peter
O’Hanley,
S.
Cryz,
C.
Simanjuntak
(2000)
Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.
Vaccine, 18 22
-
Rosanna
Lagos,
Alessio
Fasano,
Steven
Wasserman,
Valeria
Prado,
O.
Martin,
Paulina
Abrego,
G.
Losonsky,
Silvia
Alegria,
M.
Levine
(1999)
Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.
The Journal of infectious diseases, 180 5
-
K.
Kotloff,
S.
Wasserman,
S.
O'Donnell,
G.
Losonsky,
S.
Cryz,
M.
Levine
(1992)
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial
Infection and Immunity, 60